Please login to the form below

Not currently logged in
Email:
Password:

Lucid launches rare and specialist disease agency

Vivid MedComms will be headed by Alison Cantle

VividUK-based Lucid Group, has opened Vivid Medcomms, a new agency that will focus on rare diseases and be based in Buckinghamshire, UK.

Vivid will be headed up by managing director Alison Cantle, who was previously a business unit director at Lucid and has over 20 years’ medical communications experience.

She said: “Our business in rare diseases has increased threefold over the last year and making the decision to create a new stand-alone company focused on this area is an obvious choice.”

According to analysts at Evaluate Pharma sales of orphan drugs are set to account for 20% of all prescription drug sales by 2020.

The move mirrors an “industry-wide shift” towards focusing on rare and specialist disease, with revenues from orphan drugs ‘outpacing’ sales of mainstream drugs for the last decade, explained Lucid.

Cantle added: “We have developed a dedicated and talented team of account handlers and medical writers brimming with a specific skills and experience related to developing excellent comms programmes in rare diseases.

“The team are excited by the challenge and looking forward to transforming the lives of both clients and teams in this space.”

Article by
Gemma Jones

13th November 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Reaching your audiences, wherever they are. Ashfield is an international provider of outsourcing solutions to the pharmaceutical industry, dedicated to...

Latest intelligence

Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....
Pharma email marketing: Your top 12 tips
Used correctly, email can be one of the most effective and cost-efficient channels for a pharma company to use. To help you get the most from it, we've rounded up...
arrow
Patently unclear?
The challenge of protecting biotech innovations...

Infographics